Navigation Links
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Date:8/6/2009

autioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... layer of carbon atoms, may be the most amazing ... yet lightweight and flexible, graphene enables electrons to flow ... conductor, combining electrical and optical functionalities in an exceptional ... sustainable carbon revolution, with profound impact in information and ...
... GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company ... today released its 2010 Annual Report and President,s ... (10-K) provides information on the state of the ... his Letter, GeoVax,s President Robert T. McNally, Ph.D., ...
... 2011 Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: ... today announced that its chairman and CEO, Guy Cook, will ... Conference at the Hard Rock Hotel in Hollywood, Florida, on ... At the time of the presentation, a live audio and ...
Cached Biology Technology:GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot 2GeoVax Labs Announces Availability of 2010 Annual Report and President's Letter to Stockholders 2Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011 2
(Date:4/24/2014)... that the world,s oceans play a crucial role ... between Earth,s ecosystems and atmosphere. Now scientists at ... have taken a leap forward in understanding the ... use carbon dioxide to make new cells, a ... into the sea as a buffet of edible ...
(Date:4/24/2014)... NY, April 24, 2014GEN Publishing recently introduced ... publication focusing on the application of OMICs technologies ... next-gen sequencing, are beginning to transform medical care ... over the past decade-and-a-half. , "GEN,s editors and ... pharmacogenomics, genomics, metabolomics, transcriptomics, etc. etc. for years," ...
(Date:4/24/2014)... Scientific Reports journal. , CSIC researcher Carles Lalueza-Fox, ... CSIC and Pompeu Fabra University-UPF), explains: "When the Y chromosome ... it did not match with the DNA recovered from the ... and to make a functional interpretation in order to see ... , The functional genome analysis was based on two main ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3The blood preserved in the pumpkin did not belong to Louis XVI 2
... compared to last year,s record size. According to measurements made by ... tonnes, compared to the 2006 record ozone loss of 40 million ... the depth of the ozone hole. The area of this years ... Units is 24.7 million sq km, roughly the size of ...
... A team of UAB geneticists, doctors and biostatisticians has ... to study and test new treatments for neurofibromatosis, or ... a nine-institution group called the NF Consortium. The coalition ... manage multiple clinical trials held across the nation looking ...
... Keck School of Medicine of the University of Southern California ... T. & Eileen L. Norris Foundation that will be critical ... to the study of epigenetics. The grant will solidify ... holds great promise in the treatment and prevention of cancer, ...
Cached Biology News:2007 ozone hole 'smaller than usual' 22007 ozone hole 'smaller than usual' 3UAB wins $5.7M neurofibromatosis grant 2UAB wins $5.7M neurofibromatosis grant 3$10 million gift to support cutting-edge epigenome center at USC 2$10 million gift to support cutting-edge epigenome center at USC 3
... IVF are designed for human in vitro ... setup and operation, and convenience. Chamber, ... displayed on the control panel. Our signature ... by way of the thermal printer inside ...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
Biology Products: